HK1093012172
HK1093012172
CSPC PHARMA
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±45.2% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.7x).
Beta (Market Relation)
0.71x
DefensiveVolatility (5Y p.a.)
45.2% p.a.
5-Year HorizonMax Drawdown (5Y)
-57.4%
5-Year HorizonSharpe Ratio
-0.06
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Volatility Expansion (3Y > 5Y) High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -3.4% |
| 3 Years | 47.9% | -42.1% | 0.33 | +18.1% |
| 5 Years | 45.2% | -57.4% | -0.06 | -0.2% |
| 10 Years | 43.1% | -68.0% | 0.12 | +7.8% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (45.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -68.0% in the extended horizon.